{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.25","upperLimit":"66.53","value":"41.67"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.","dispersionType":"95% Confidence Interval","groups":[{"description":"IND II: Pts receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, sorafenib tosylate PO on days 9-36.\n\nINT I: Pts receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and sorafenib tosylate PO on daily on days 6-28.\n\nINT II: Pts receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), sorafenib tosylate PO on days 7-34.\n\nSCT (HR patients with matched family \\[MFD\\] or unrelated donor):\n\nPts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2, busulfan IV over 2 hours 4 times daily on days -5 to -2.\n\nPatients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.\n\nMAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.","id":"OG000","title":"Arm C (Cohort 1)"}],"paramType":"NUMBER","populationDescription":"Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of OS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"OS for Patients on Arm C, Cohort 1","type":"SECONDARY","unitOfMeasure":"percentage of patients"}